IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Federated Hermes Inc. (2024)

Federated Hermes Inc. decreased its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 9.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,525 shares of the medical research company’s stock after selling 18,688 shares during the period. Federated Hermes Inc. owned 0.09% of IQVIA worth $39,687,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of IQV. International Assets Investment Management LLC acquired a new position in IQVIA in the fourth quarter valued at $13,759,000. Schwartz Investment Counsel Inc. grew its stake in IQVIA by 4.1% during the 4th quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after buying an additional 7,050 shares during the last quarter. Dfpg Investments LLC acquired a new position in IQVIA during the fourth quarter worth approximately $1,106,000. Sei Investments Co. lifted its stake in IQVIA by 20.2% in the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock valued at $18,641,000 after buying an additional 15,913 shares during the last quarter. Finally, Duality Advisers LP acquired a new stake in shares of IQVIA in the third quarter valued at approximately $491,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the subject of several research reports. Guggenheim downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. BTIG Research initiated coverage on shares of IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 target price for the company. UBS Group boosted their price target on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Robert W. Baird increased their price objective on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Finally, SVB Leerink assumed coverage on IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $256.80.

Read Our Latest Stock Report on IQVIA

Insider Transactions at IQVIA

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 in the last 90 days. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Up 0.4 %

IQV stock opened at $228.09 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The company’s 50-day moving average price is $244.82 and its 200 day moving average price is $221.87. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a market cap of $41.40 billion, a P/E ratio of 31.29, a P/E/G ratio of 2.21 and a beta of 1.50.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.54 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

• Five stocks we like better than IQVIA
• What is Put Option Volume?
• MarketBeat Week in Review – 4/15 – 4/19
• How to Invest in the Best Canadian Stocks
• Comprehensive Analysis of PayPal Stock
• Health Care Stocks Explained: Why You Might Want to Invest
• Intuitive Surgical Stock Can Trend Much Higher This Year

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.